Michel Ducreux

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1748829/publications.pdf

Version: 2024-02-01

285	40,510	4942 84	2617 194
papers	citations	h-index	g-index

300	300	300	33097
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. New England Journal of Medicine, 2011, 364, 1817-1825.	13.9	6,140
2	Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. New England Journal of Medicine, 2020, 382, 1894-1905.	13.9	3,828
3	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology, 2016, 27, 1386-1422.	0.6	2,545
4	KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer. Cancer Research, 2006, 66, 3992-3995.	0.4	2,116
5	Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203. Journal of Clinical Oncology, 2006, 24, 4620-4625.	0.8	1,551
6	KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. Journal of Clinical Oncology, 2008, 26, 374-379.	0.8	1,398
7	Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene, 2010, 29, 482-491.	2.6	937
8	Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2010, 28, 4706-4713.	0.8	909
9	Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer. Journal of Clinical Oncology, 2009, 27, 5924-5930.	0.8	645
10	Final Results of a Randomized Phase III Trial of Sequential High-Dose Methotrexate, Fluorouracil, and Doxorubicin Versus Etoposide, Leucovorin, and Fluorouracil Versus Infusional Fluorouracil and Cisplatin in Advanced Gastric Cancer: A Trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Journal of Clinical Oncology, 2000, 18, 2648-2657.	0.8	522
11	Patients With Initially Unresectable Colorectal Liver Metastases: Is There a Possibility of Cure?. Journal of Clinical Oncology, 2009, 27, 1829-1835.	0.8	514
12	Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. Journal of the National Cancer Institute, 2017, 109, .	3.0	466
13	Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. British Journal of Cancer, 1999, 81, 1351-1355.	2.9	455
14	Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer, 2001, 92, 71-76.	2.0	390
15	Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Journal of Hepatology, 1998, 29, 129-134.	1.8	384
16	Radiofrequency Ablation of 100 Hepatic Metastases with a Mean Follow-Up of More Than 1 Year. American Journal of Roentgenology, 2000, 175, 1619-1625.	1.0	371
17	Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science, 2015, 350, 972-978.	6.0	367
18	Midterm Local Efficacy and Survival after Radiofrequency Ablation of Lung Tumors with Minimum Follow-up of 1 Year: Prospective Evaluation. Radiology, 2006, 240, 587-596.	3.6	347

#	Article	IF	Citations
19	Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncology, The, 2014, 15, 819-828.	5.1	345
20	Detection of Liver Metastases From Endocrine Tumors: A Prospective Comparison of Somatostatin Receptor Scintigraphy, Computed Tomography, and Magnetic Resonance Imaging. Journal of Clinical Oncology, 2005, 23, 70-78.	0.8	339
21	Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Annals of Oncology, 2002, 13, 267-272.	0.6	317
22	During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. British Journal of Surgery, 2002, 86, 784-788.	0.1	317
23	Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. The Lancet Gastroenterology and Hepatology, 2021, 6, 17-29.	3.7	307
24	Induction Chemotherapy and Dose Intensification of the Radiation Boost in Locally Advanced Anal Canal Carcinoma: Final Analysis of the Randomized UNICANCER ACCORD 03 Trial. Journal of Clinical Oncology, 2012, 30, 1941-1948.	0.8	305
25	Hepatic Tumors Treated with Percutaneous Radio-frequency Ablation: CT and MR Imaging Follow-up. Radiology, 2002, 223, 255-262.	3.6	303
26	Are G3 ENETS neuroendocrine neoplasms heterogeneous?. Endocrine-Related Cancer, 2013, 20, 649-657.	1.6	275
27	Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.. Journal of Clinical Oncology, 1998, 16, 2739-2744.	0.8	273
28	Treatment of carcinoid syndrome. , 2000, 88, 770-776.		240
29	Hepatic and Extrahepatic Colorectal Metastases: When Resectable, Their Localization Does Not Matter, But Their Total Number Has a Prognostic Effect. Annals of Surgical Oncology, 2005, 12, 900-909.	0.7	240
30	Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. European Radiology, 2003, 13, 136-140.	2.3	235
31	ERCC1 Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal Cancer. Clinical Cancer Research, 2005, 11, 6212-6217.	3.2	224
32	Is There a Possibility of a Cure in Patients With Colorectal Peritoneal Carcinomatosis Amenable to Complete Cytoreductive Surgery and Intraperitoneal Chemotherapy?. Annals of Surgery, 2013, 257, 1065-1071.	2.1	219
33	Hepatic Arterial Oxaliplatin Infusion Plus Intravenous Chemotherapy in Colorectal Cancer With Inoperable Hepatic Metastases: A Trial of the Gastrointestinal Group of the FÃ©dÃ©ration Nationale des Centres de Lutte Contre le Cancer. Journal of Clinical Oncology, 2005, 23, 4881-4887.	0.8	215
34	Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: A 15-year single center prospective study. Surgery, 2003, 133, 375-382.	1.0	212
35	Results of Systematic Second-look Surgery Plus HIPEC in Asymptomatic Patients Presenting a High Risk of Developing Colorectal Peritoneal Carcinomatosis. Annals of Surgery, 2011, 254, 289-293.	2.1	206
36	Advanced Hepatocellular Carcinoma: Early Evaluation of Response to Bevacizumab Therapy at Dynamic Contrast-enhanced US with Quantificationâ€"Preliminary Results. Radiology, 2011, 258, 291-300.	3.6	201

#	Article	IF	Citations
37	Surgery for lung metastases from colorectal cancer: analysis of prognostic factors.. Journal of Clinical Oncology, 1996, 14, 2047-2053.	0.8	194
38	Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients. Journal of the American College of Surgeons, 1998, 187, 487-493.	0.2	193
39	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 420-435.	5.1	191
40	Percutaneous Radiofrequency Ablation of Hepatic Tumors During Temporary Venous Occlusion. American Journal of Roentgenology, 2002, 178, 53-59.	1.0	190
41	A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Annals of Oncology, 2009, 20, 674-680.	0.6	189
42	Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC). Cancer, 2007, 109, 1384-1390.	2.0	187
43	Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Annals of Thoracic Surgery, 1998, 66, 214-218.	0.7	185
44	The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. American Journal of Gastroenterology, 2000, 95, 3276-3281.	0.2	184
45	Hepatic Resection After Rescue Cetuximab Treatment for Colorectal Liver Metastases Previously Refractory to Conventional Systemic Therapy. Journal of Clinical Oncology, 2007, 25, 4593-4602.	0.8	183
46	Final results from a randomized phase 3 study of FOLFIRI Â± panitumumab for second-line treatment of metastatic colorectal cancer. Annals of Oncology, 2014, 25, 107-116.	0.6	182
47	Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients.. Gut, 1996, 39, 279-283.	6.1	181
48	Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 991-1001.	5.1	179
49	Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Research, 2003, 63, 5738-44.	0.4	179
50	Transcatheter chemoembolization of progressive carcinoid liver metastasis.. Radiology, 1993, 189, 541-547.	3.6	174
51	MR Imaging of Hepatic Metastases Caused by Neuroendocrine Tumors: Comparing Four Techniques. American Journal of Roentgenology, 2003, 180, 121-128.	1.0	172
52	Hepatic Arterial Infusion of Oxaliplatin and Intravenous LV5FU2 in Unresectable Liver Metastases from Colorectal Cancer after Systemic Chemotherapy Failure. Annals of Surgical Oncology, 2008, 15, 219-226.	0.7	168
53	Results of R0 Resection for Colorectal Liver Metastases Associated With Extrahepatic Disease. Annals of Surgical Oncology, 2004, 11, 274-280.	0.7	161
54	Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: Lipiodol vs. drug-eluting beads. Journal of Hepatology, 2012, 56, 609-617.	1.8	161

#	Article	IF	Citations
55	Rapid and Sustained Relief from the Symptoms of Carcinoid Syndrome: Results from an Open 6-Month Study of the 28-Day Prolonged-Release Formulation of Lanreotide. Neuroendocrinology, 2004, 80, 244-251.	1.2	152
56	Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. Clinical Cancer Research, 2015, 21, 5469-5479.	3.2	152
57	Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. Journal of Clinical Oncology, 2010, 28, 2556-2564.	0.8	146
58	An update on treatment options for pancreatic adenocarcinoma. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987556.	1.4	144
59	Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Annals of Oncology, 1998, 9, 653-656.	0.6	141
60	Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Annals of Oncology, 2005, 16, 1488-1497.	0.6	138
61	Current standards and new innovative approaches for treatment of pancreatic cancer. European Journal of Cancer, 2016, 57, 10-22.	1.3	138
62	Results of Systematic Second-Look Surgery in Patients at High Risk of Developing Colorectal Peritoneal Carcinomatosis. Annals of Surgery, 2008, 247, 445-450.	2.1	136
63	Capecitabine plus oxaliplatin (XELOX) versus 5â€fluorouracil/leucovorin plus oxaliplatin (FOLFOXâ€6) as firstâ€line treatment for metastatic colorectal cancer. International Journal of Cancer, 2011, 128, 682-690.	2.3	131
64	Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer â€“ Differential treatment strategies for subtypes of early gastroesophageal cancer. European Journal of Cancer, 2012, 48, 2941-2953.	1.3	129
65	Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD) Tj ETQq1 1 0.784314 rgBT /Ov	5.1	128
66	Outcome of Posthepatectomy-Missing Colorectal Liver Metastases after Complete Response to Chemotherapy: Impact of Adjuvant Intra-arterial Hepatic Oxaliplatin. Annals of Surgical Oncology, 2007, 14, 3188-3194.	0.7	125
67	Management of malignant hilar biliary obstruction by endoscopy results and prognostic factors. Digestive Diseases and Sciences, 1992, 37, 778-783.	1.1	124
68	Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases. , 1998, 69, 88-93.		122
69	Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial. European Journal of Cancer, 2017, 87, 122-130.	1.3	120
70	Gender medicine and oncology: report and consensus of an ESMO workshop. Annals of Oncology, 2019, 30, 1914-1924.	0.6	120
71	Prolonged Survival of Initially Unresectable Hepatic Colorectal Cancer Patients Treated With Hepatic Arterial Infusion of Oxaliplatin Followed by Radical Surgery of Metastases. Annals of Surgery, 2010, 251, 686-691.	2.1	116
72	Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. Annals of Oncology, 2004, 15, 1558-1565.	0.6	114

#	Article	IF	Citations
73	A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Annals of Oncology, 2002, 13, 1185-1191.	0.6	113
74	Liver abscess formation after local treatment of liver tumors. Hepatology, 1996, 23, 1436-1440.	3.6	112
75	Efficacy, Safety, and Biomarkers of Single-Agent Bevacizumab Therapy in Patients with Advanced Hepatocellular Carcinoma. Oncologist, 2012, 17, 1063-1072.	1.9	112
76	GEP-NETS UPDATE: Interventional radiology: role in the treatment of liver metastases from GEP-NETs. European Journal of Endocrinology, 2015, 172, R151-R166.	1.9	109
77	Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocrine-Related Cancer, 2009, 16, 585-597.	1.6	105
78	Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials. European Journal of Cancer, 2015, 51, 166-176.	1.3	105
79	Dosage Adjustment and Pharmacokinetic Profile of Irinotecan in Cancer Patients With Hepatic Dysfunction. Journal of Clinical Oncology, 2002, 20, 4303-4312.	0.8	104
80	Targeted therapy in metastatic colorectal cancer â€“ An example of personalised medicine in action. Cancer Treatment Reviews, 2013, 39, 592-601.	3.4	104
81	Cetuximab plus Gemcitabine-Oxaliplatin (GEMOX) in Patients with Refractory Advanced Intrahepatic Cholangiocarcinomas. Oncology, 2007, 72, 105-110.	0.9	96
82	Peritoneal carcinomatosis of colorectal origin. Gastroenterologie Clinique Et Biologique, 2006, 30, 1200-1204.	0.9	95
83	Irinotecan Combined With Bolus Fluorouracil, Continuous Infusion Fluorouracil, and High-Dose Leucovorin Every Two Weeks (LV5FU2 Regimen): A Clinical Dose-Finding and Pharmacokinetic Study in Patients With Pretreated Metastatic Colorectal Cancer. Journal of Clinical Oncology, 1999, 17, 2901-2901.	0.8	94
84	Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. Journal of Surgical Oncology, 2004, 86, 4-9.	0.8	94
85	Performance of 18Fluorodeoxyglucose-Positron Emission Tomography and Somatostatin Receptor Scintigraphy for High Ki67 (â‰¥10%) Well-Differentiated Endocrine Carcinoma Staging. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 665-671.	1.8	93
86	Malignant Gastroduodenal Obstruction: Palliation with Self-expanding Metallic Stents. Journal of Vascular and Interventional Radiology, 2005, 16, 247-253.	0.2	91
87	Tumour spheres with inverted polarity drive the formation of peritoneal metastases in patients with hypermethylated colorectal carcinomas. Nature Cell Biology, 2018, 20, 296-306.	4.6	88
88	The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer. Current Oncology Reports, 2013, 15, 182-189.	1.8	85
89	mTOR as a therapeutic target in patients with gastric cancer. International Journal of Cancer, 2012, 130, 491-496.	2.3	84
90	Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial) â€“ A phase II non-randomised trial. European Journal of Cancer, 2014, 50, 3107-3115.	1.3	82

#	Article	IF	Citations
91	Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model. Anti-Cancer Drugs, 2004, 15, 647-650.	0.7	81
92	Combination Chemotherapy in Advanced Small Bowel Adenocarcinoma. Oncology, 2005, 69, 290-294.	0.9	81
93	Systemic treatment of pancreatic cancer revisited. Seminars in Oncology, 2019, 46, 28-38.	0.8	81
94	A Randomized Phase II Trial of Three Intensified Chemotherapy Regimens in First-Line Treatment of Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases. The METHEP Trial. Annals of Surgical Oncology, 2013, 20, 4289-4297.	0.7	80
95	Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives. European Journal of Cancer, 2016, 59, 160-170.	1.3	78
96	Adjuvant Chemotherapy After Resection of Colorectal Liver Metastases in Patients at High Risk of Hepatic Recurrence. Annals of Surgery, 2013, 257, 114-120.	2.1	76
97	Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. European Journal of Cancer, 2016, 63, 11-24.	1.3	73
98	Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Digestive and Liver Disease, 2018, 50, 768-779.	0.4	73
99	Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas. Surgery, 2005, 137, 411-416.	1.0	72
100	Molecular targeted therapy of BRAF-mutant colorectal cancer. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591985649.	1.4	72
101	Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer, 2003, 98, 2664-2670.	2.0	71
102	Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial) â€“ A phase II non-randomised trial. European Journal of Cancer, 2014, 50, 3098-3106.	1.3	69
103	Prognostic Similarities and Differences in Optimally Resected Liver Metastases and Peritoneal Metastases From Colorectal Cancers. Annals of Surgery, 2015, 261, 157-163.	2.1	68
104	Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival. Annals of Oncology, 2002, 13, 721-729.	0.6	67
105	Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1471-1478.	0.4	65
106	Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas. Cancer, 2007, 110, 265-274.	2.0	63
107	Systemic treatment of advanced hepatocellular carcinoma: From disillusions to new horizons. European Journal of Cancer, 2015, 51, 327-339.	1.3	63
108	Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: A multicenter phase II study with dose adjustment according to baseline serum bilirubin level. European Journal of Cancer, 2006, 42, 456-459.	1.3	62

#	Article	IF	Citations
109	Percutaneous Femoral Implantation of an Arterial Port Catheter for Intraarterial Chemotherapy: Feasibility and Predictive Factors of Long-term Functionality. Journal of Vascular and Interventional Radiology, 2010, 21, 1681-1688.	0.2	62
110	Diagnosis, and prognosis of AIDS-related cholangitis. Aids, 1995, 9, 875-880.	1.0	61
111	Phase I, Dose-Finding, and Pharmacokinetic Study of Raltitrexed Combined With Oxaliplatin in Patients With Advanced Cancer. Journal of Clinical Oncology, 2000, 18, 2293-2300.	0.8	61
112	Screening and surveillance in hereditary gastrointestinal cancers: Recommendations from the European Society of Digestive Oncology (ESDO)Âexpert discussion at the 20th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona, June 2018. European Journal of Cancer, 2018, 104, 91-103.	1.3	60
113	Intestinal bacterial Î²-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity. , 2019, 199, 1-15.		59
114	Results of a randomized phase 3 study evaluating the potential benefit of a second-look surgery plus HIPEC in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 53	0.8	59
115	Treatment of Advanced Pancreatic Cancer. Seminars in Oncology, 2007, 34, S25-S30.	0.8	57
116	Artificially Induced Pneumothorax for Percutaneous Transthoracic Radiofrequency Ablation of Tumors in the Hepatic Dome: Initial Experience. Radiology, 2005, 236, 666-670.	3.6	56
117	Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). European Journal of Cancer, 2014, 50, 2983-2993.	1.3	56
118	Benefits of Contrast-Enhanced Sonography for the Detection of Liver Lesions: Comparison with Histologic Findings. American Journal of Roentgenology, 2008, 190, 683-690.	1.0	55
119	Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP). Digestive and Liver Disease, 2017, 49, 831-840.	0.4	53
120	Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, 3568-3568.	0.8	53
121	A Simple Tumor Load-Based Nomogram for Surgery in Patients with Colorectal Liver and Peritoneal Metastases. Annals of Surgical Oncology, 2014, 21, 2052-2058.	0.7	52
122	Leukocytosis and neutrophilia predicts outcome in anal cancer. Radiotherapy and Oncology, 2017, 122, 137-145.	0.3	50
123	Complete Radiological Response of Colorectal Liver Metastases after Chemotherapy: What Can We Expect?. Digestive Surgery, 2011, 28, 114-120.	0.6	49
124	Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study. European Journal of Cancer, 2019, 123, 146-154.	1.3	46
125	Screening for Multiple Endocrine Neoplasia Type 1 and Hormonal Production in Apparently Sporadic Neuroendocrine Tumors1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 69-75.	1.8	45
126	Improving outcomes in colorectal cancer: Where do we go from here?. European Journal of Cancer, 2013, 49, 2476-2485.	1.3	43

#	Article	IF	Citations
127	3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. European Journal of Cancer, 2017, 79, 41-49.	1.3	43
128	Cancer of the anal region. Critical Reviews in Oncology/Hematology, 2002, 43, 77-92.	2.0	42
129	Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects. European Journal of Cancer, 2017, 79, 15-22.	1.3	42
130	The role of image-guided therapy in the management of colorectal cancer metastatic disease. European Journal of Cancer, 2017, 75, 231-242.	1.3	40
131	Cancer of the anal region. Critical Reviews in Oncology/Hematology, 2019, 135, 115-127.	2.0	40
132	Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids. European Journal of Cancer, 2017, 75, 259-267.	1.3	39
133	Chromogranin a Measurement in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma: Screening for False Positives and a Prospective Follow-Up Study. International Journal of Biological Markers, 2011, 26, 94-101.	0.7	38
134	IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma.. Journal of Clinical Oncology, 2018, 36, TPS4141-TPS4141.	0.8	38
135	Thyroid metastases from colorectal cancer: The Institut Gustave Roussy experience. European Journal of Cancer, 2006, 42, 1756-1759.	1.3	37
136	Tumor Marker Evolution: Comparison with Imaging for Assessment of Response to Chemotherapy in Patients with Colorectal Liver Metastases. Annals of Surgical Oncology, 2010, 17, 1010-1023.	0.7	37
137	Characterization, Prognosis, and Treatment of Patients With Metastatic Lung Carcinoid Tumors. Journal of Thoracic Oncology, 2019, 14, 993-1002.	0.5	37
138	Phase I and Pharmacokinetic Study of Docetaxel and Irinotecan in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2000, 18, 3545-3552.	0.8	36
139	Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients. Clinical Cancer Research, 2014, 20, 265-272.	3.2	36
140	Leukocytosis and neutrophilia predict outcome in locally advanced esophageal cancer treated with definitive chemoradiation. Oncotarget, 2017, 8, 11579-11588.	0.8	36
141	Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Gastroenterologie Clinique Et Biologique, 2006, 30, 357-363.	0.9	35
142	Accelerated fractionation in esophageal cancers: A multivariate analysis on 88 patients. International Journal of Radiation Oncology Biology Physics, 1997, 38, 1013-1018.	0.4	33
143	Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG. Gastric Cancer, 2017, 20, 904-912.	2.7	33
144	Hepatic Intraarterial¹³¹I Iodized Oil for Treatment of Hepatocellular Carcinoma in Patients with Impeded Portal Venous Flow. Radiology, 1999, 212, 665-668.	3.6	31

#	Article	IF	Citations
145	Patients Operated On for Initially Unresectable Colorectal Liver Metastases With Missing Metastases Experience a Favorable Long-Term Outcome. Annals of Surgery, 2011, 254, 114-118.	2.1	30
146	MODULâ€"a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1197-1204.	1.2	30
147	Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials. European Journal of Cancer, 2018, 98, 1-9.	1.3	30
148	Predisposing Factors of Liver Necrosis after Transcatheter Arterial Chemoembolization in Liver Metastases from Neuroendocrine Tumor. CardioVascular and Interventional Radiology, 2015, 38, 372-380.	0.9	29
149	Joint Model for Left-Censored Longitudinal Data, Recurrent Events and Terminal Event: Predictive Abilities of Tumor Burden for Cancer Evolution With Application to the FFCD 2000â€"05 Trial. Biometrics, 2016, 72, 907-916.	0.8	28
150	Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenaseâ€"mutated intrahepatic cholangiocarcinomas. European Journal of Cancer, 2018, 90, 83-91.	1.3	28
151	Biliary tract neoplasms: update 2003. Current Opinion in Oncology, 2004, 16, 364-371.	1.1	27
152	Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?. European Journal of Cancer, 2017, 81, 161-173.	1.3	27
153	Ex Vivo Sentinel Lymph Node Study For Rectal Adenocarcinoma: Preliminary Study. World Journal of Surgery, 2005, 29, 1166-1170.	0.8	26
154	Fatigue and physical activity in cancer survivors: A crossâ€sectional populationâ€based study. Cancer Medicine, 2019, 8, 2535-2544.	1.3	26
155	Serum Gamma-Glutamyl-Transferase Independently Predicts Outcome After Transarterial Chemoembolization of Hepatocellular Carcinoma: External Validation. CardioVascular and Interventional Radiology, 2012, 35, 1102-1108.	0.9	25
156	Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy. Annals of Surgical Oncology, 2017, 24, 3640-3646.	0.7	25
157	Impact of COVID-19 on healthcare organisation and cancer outcomes. European Journal of Cancer, 2021, 153, 123-132.	1.3	25
158	Usefulness of Guiding Needles for Radiofrequency Ablative Treatment of Liver Tumors. CardioVascular and Interventional Radiology, 2006, 29, 650-654.	0.9	24
159	Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, LBA387-LBA387.	0.8	24
160	The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. European Journal of Cancer, 2019, 112, 1-8.	1.3	23
161	Adjuvant treatment of pancreatic cancer. Current Opinion in Oncology, 2019, 31, 346-353.	1.1	23
162	Sentinel lymph nodes of colorectal carcinoma: reappraisal of 123 cases. Gastroenterologie Clinique Et Biologique, 2007, 31, 281-285.	0.9	22

#	Article	IF	Citations
163	Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona. European Journal of Cancer, 2017, 86, 305-317.	1.3	22
164	Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial â€“ PACHA-01 (NCT02494973). BMC Cancer, 2018, 18, 787.	1.1	22
165	A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget, 2015, 6, 14139-14152.	0.8	22
166	Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2009, 135, 749-752.	1.2	21
167	Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies. Investigational New Drugs, 2014, 32, 1028-1035.	1.2	21
168	The development of new agents and molecular classifications. Nature Reviews Clinical Oncology, 2016, 13, 69-70.	12.5	21
169	Peritoneal and extraperitoneal relapse after previous curative treatment of peritoneal metastases from colorectal cancer: What survival can we expect?. European Journal of Cancer, 2018, 100, 94-103.	1.3	20
170	RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma.. Journal of Clinical Oncology, 2018, 36, 5-5.	0.8	19
171	Phase I and Pharmacokinetic Study of the Camptothecin Analog DX-8951f Administered as a 30-Minute Infusion Every 3 Weeks in Patients With Advanced Cancer. Journal of Clinical Oncology, 2000, 18, 3986-3992.	0.8	18
172	Regional chemotherapeutic techniques for liver tumors: current knowledge and future directions. Surgical Clinics of North America, 2004, 84, 607-625.	0.5	18
173	Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228). British Journal of Cancer, 2017, 117, 965-973.	2.9	18
174	Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer. Cancers, 2021, 13, 4724.	1.7	18
175	Combined radiotherapy, 5-fluorouracil continuous infusion and weekly oxaliplatin in advanced rectal cancer: A phase I study. European Journal of Cancer, 2005, 41, 2861-2867.	1.3	17
176	The long-term impact of hyperthermic intraperitoneal chemotherapy on survivors treated for peritoneal carcinomatosis: a cross-sectional study. Supportive Care in Cancer, 2009, 17, 1255-1261.	1.0	17
177	Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study. Digestive and Liver Disease, 2016, 48, 441-445.	0.4	17
178	Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience. Cancers, 2021, 13, 5366.	1.7	17
179	High-Dose Irinotecan plus LV5FU2 or Simplified LV5FU (HD-FOLFIRI) for Patients with Untreated Metastatic Colorectal Cancer: A New Way to Allow Resection of Liver Metastases?. Oncology, 2008, 74, 17-24.	0.9	16
180	Intervention in gastro-enteropancreatic neuroendocrine tumours. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012, 26, 855-865.	1.0	16

#	Article	IF	Citations
181	Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer. European Journal of Cancer, 2020, 137, 117-126.	1.3	16
182	Evaluating iatrogenic prescribing: Development of an oncology-focused trigger tool. European Journal of Cancer, 2015, 51, 427-435.	1.3	15
183	Treatment sequence of synchronously (liver) metastasized colon cancer. Digestive and Liver Disease, 2016, 48, 1119-1123.	0.4	15
184	RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014. Digestive and Liver Disease, 2018, 50, 507-512.	0.4	15
185	Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index â‰¥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE). Neuroendocrinology, 2018, 106, 38-46.	1.2	15
186	Simultaneous high-dose external irradiation and daily cisplatin in unresectable, non-metastatic adenocarcinoma of the pancreas: a phase Iâ€“II study. Radiotherapy and Oncology, 1997, 45, 129-132.	0.3	14
187	Evaluation of Clinical Efficacy of New Medical Treatments in Advanced Colorectal Cancer. Results of a Workshop Organized by the Eortc Gitccg. Tumori, 1998, 84, 335-347.	0.6	14
188	Mutational status of EGFR, BRAF, PI3KCA and JAK2 genes in endocrine tumors. International Journal of Cancer, 2009, 124, 751-753.	2.3	14
189	Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development. Cancer Treatment Reviews, 2015, 41, 129-135.	3.4	14
190	Intra-arterial therapies for colorectal cancer liver metastases (radioembolization excluded). Bulletin Du Cancer, 2017, 104, 402-406.	0.6	14
191	5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathy. Anti-Cancer Drugs, 2019, 30, 313-317.	0.7	14
192	An appendix carcinoid tumor in a patient with hereditary nonpolyposis colorectal cancer. Human Pathology, 2004, 35, 1564-1567.	1.1	13
193	Antitumoral Effect of Celecoxib in Hepatocellular Carcinoma. Journal of Clinical Oncology, 2005, 23, 4805-4806.	0.8	13
194	Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases. European Journal of Cancer, 2020, 138, 89-98.	1.3	13
195	A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma.. Journal of Clinical Oncology, 2018, 36, TPS3110-TPS3110.	0.8	13
196	Imagine a world without cancer. BMC Cancer, 2014, 14, 186.	1.1	12
197	Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT). Clinical Colorectal Cancer, 2017, 16, 129-140.e4.	1.0	12
198	Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial. Cancer Chemotherapy and Pharmacology, 2017, 79, 9-16.	1.1	12

#	Article	IF	Citations
199	5-Fluorouracil-induced hyperammonaemic encephalopathy: A French national survey. European Journal of Cancer, 2020, 129, 32-40.	1.3	12
200	Oxaliplatin and 5-Fluorouracil in Advanced Well-Differentiated Digestive Neuroendocrine Tumors: A Multicenter National Retrospective Study from the French Group of Endocrine Tumors. Neuroendocrinology, 2022, 112, 537-546.	1.2	12
201	Efficacy and safety of bevacizumab combined with capecitabine in progressive, metastatic well-differentiated digestive endocrine tumors (BETTER study).. Journal of Clinical Oncology, 2012, 30, 4071-4071.	0.8	12
202	Simultaneous decompression colonoscopy and radiologic G-tube insertion in a patient with megacolon because of chronic colonic pseudo-obstruction. Gastrointestinal Endoscopy, 2005, 62, 975-976.	0.5	11
203	Splenic infarction and bevacizumab. Lancet Oncology, The, 2006, 7, 1038.	5.1	11
204	Pancreatic cancer: From pathogenesis to cure. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 997-1014.	1.0	11
205	Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival. Radiation Oncology, 2011, 6, 124.	1.2	11
206	Frequency and characterization of gastroâ€“enteroâ€“pancreatic neuroendocrine tumor patients with high-grade of uptake at somatostatin receptor scintigraphy. Endocrine-Related Cancer, 2013, 20, 229-239.	1.6	11
207	Not All Patients with a Pancreatic Neuroendocrine Tumour Will Benefit from All Approved or Recommended Therapeutic Options: A Real-Life Retrospective Study. Neuroendocrinology, 2017, 105, 26-34.	1.2	11
208	Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position. European Journal of Cancer, 2020, 135, 103-112.	1.3	11
209	Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER). European Journal of Cancer, 2021, 150, 232-239.	1.3	11
210	More than a Gel & Hyaluronic Acid, a Central Component in the Microenvironment of Pancreatic Cancer. European Oncology and Haematology, 2018, 14, 40.	0.0	11
211	Future directions in drug development in pancreatic cancer. Seminars in Oncology, 2021, 48, 47-56.	0.8	10
212	Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers. Expert Opinion on Investigational Drugs, 2021, 30, 401-409.	1.9	10
213	Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial). Anticancer Research, 2006, 26, 3877-83.	0.5	10
214	Abdominoperineal resection combined with pre- and postoperative radiation therapy in the treatment of low-lying rectal carcinoma. International Journal of Radiation Oncology Biology Physics, 1997, 37, 59-65.	0.4	9
215	Final results from study 181: Randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2012, 30, 387-387.	0.8	9
216	Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer. European Journal of Cancer, 2016, 68, 163-172.	1.3	8

#	Article	IF	Citations
217	Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors. Investigational New Drugs, 2017, 35, 247-249.	1.2	8
218	Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in Oncology. Computational and Mathematical Methods in Medicine, 2018, 2018, 1-8.	0.7	8
219	Management of digestive cancers during the COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR). Digestive and Liver Disease, 2021, 53, 306-308.	0.4	8
220	Efficacy and safety of bevacizumab combined with chemotherapy in the treatment of patients with metastatic well-differentiated duodeno-pancreatic endocrine tumors (BETTER study).. Journal of Clinical Oncology, 2012, 30, 4036-4036.	0.8	8
221	IMPALA, a randomized phase III study in patients with metastatic colorectal carcinoma: Immunomodulatory maintenance therapy with TLR-9 agonist MGN1703.. Journal of Clinical Oncology, 2015, 33, TPS791-TPS791.	0.8	8
222	Prognostic value of circulating tumor cells in advanced gastroesophageal adenocarcinomas in the randomized trial PRODIGE 17- MEGA (Unicancer GI-AGEO).. Journal of Clinical Oncology, 2016, 34, 4030-4030.	0.8	8
223	Complete, Long-Standing Regression of Hepatocellular Carcinoma After Somatostatin Analogue Treatment. Journal of Clinical Oncology, 2007, 25, e15-e16.	0.8	7
224	Cholangiocarcinoma with STRN-ALK translocation treated with ALK inhibitors. Digestive and Liver Disease, 2021, 53, 1664-1665.	0.4	6
225	Constitutive single nucleotide polymorphisms (SNP) assessment for predicting tolerability and efficacy of triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-CET) in patients (pts) with liver metastases from colorectal cancer (LM-CRC) (European trial OPTILIV, NCT00852228).. Journal of Clinical Oncology, 2014, 32, 3593-3593.	0.8	6
226	Patient-derived organoids identify an apico-basolateral polarity switch associated with survival in colorectal cancer. Journal of Cell Science, 2022, 135, .	1.2	6
227	Bevacizumab and Subtype-Adapted Chemotherapy Backbone in Neuroendocrine Tumors. Journal of Clinical Oncology, 2013, 31, 976-977.	0.8	5
228	Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: A non-comparative randomized phase II trial. Digestive and Liver Disease, 2014, 46, 950-955.	0.4	5
229	Body-mass index, cancer, and implications for screening. Lancet Oncology, The, 2015, 16, e102-e103.	5.1	5
230	Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals. European Journal of Cancer, 2016, 66, 75-82.	1.3	5
231	Are we reproducible in measurement of NET liver metastasis?. Digestive and Liver Disease, 2017, 49, 1121-1127.	0.4	5
232	Vision loss after chemotherapy: an irinotecan-induced retinopathy. European Journal of Cancer, 2019, 112, 80-82.	1.3	5
233	Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49. Digestive and Liver Disease, 2022, 54, 324-330.	0.4	5
234	Development of a Decision-Aid Form (DAF) for the stratification of care in a French comprehensive cancer center, a tool to support identification of care goals. Annals of Palliative Medicine, 2022, 11, 1876-1887.	0.5	5

#	Article	IF	Citations
235	Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes?. Hepatic Oncology, 2016, 3, 109-118.	4.2	4
236	Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan. Journal of the Formosan Medical Association, 2021, 120, 2023-2031.	0.8	4
237	Intercontinental Multidisciplinary Oncology Videoconferencing for Rare and Complex Cancer: An Alternative to Systematic Transfer. JCO Oncology Practice, 2021, 17, e1311-e1317.	1.4	4
238	Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases. , 1998, 69, 88.		4
239	Cost-Effectiveness Analysis of First-Line Chemotherapies in Metastatic Colorectal Cancer. Oncology, 2006, 71, 40-48.	0.9	3
240	Effect of XELOX on functional ability among elderly patients with metastatic colorectal cancer: Results from the FNCLCC/GERICO 02 phase II study. Journal of Geriatric Oncology, 2011, 2, 105-111.	0.5	3
241	Carcinoid syndrome in neuroendocrine tumors: a prognostic effect?. Lancet Oncology, The, 2017, 18, 426-428.	5.1	3
242	Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours. Digestive and Liver Disease, 2017, 49, 568-571.	0.4	3
243	Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancerâ€"A definite conclusion?. Seminars in Oncology, 2017, 44, 129-131.	0.8	3
244	Long-Term Results after Surgical Resection of Peritoneal Metastasis from Neuroendocrine Tumors. Neuroendocrinology, 2021, 111, 599-608.	1.2	3
245	Post-Radiation Grade 3 Neuroendocrine Carcinoma: A New Entity?. Neuroendocrinology, 2021, 111, 139-145.	1.2	3
246	Impact of tumor location on outcomes in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): An interim analysis from the prospective, observational CORRELATE study.. Journal of Clinical Oncology, 2017, 35, 3567-3567.	0.8	3
247	CA 19-9 and Pancreatic Carcinoma, a Revival?. Oncology Research and Treatment, 2007, 30, 12-13.	0.8	2
248	Reply to R. Glynne-Jones et al. Journal of Clinical Oncology, 2013, 31, 165-166.	0.8	2
249	Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion?. OncoTargets and Therapy, 2013, 6, 95.	1.0	2
250	Bevacizumab versus antiâ€"epidermal growth factor receptor in first-line metastatic colorectal cancer. A meta-analysis: The last building block?. European Journal of Cancer, 2016, 69, 178-179.	1.3	2
251	Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy. Digestive and Liver Disease, 2019, 51, 1185-1191.	0.4	2
252	An appraisal of emerging second line therapies for metastatic colorectal cancer. Expert Review of Gastroenterology and Hepatology, 2021, 15, 165-179.	1.4	2

#	Article	IF	Citations
253	Hepatic arterial infusion of chemotherapy as an option in a multimodal treatment of metastatic squamous cell carcinoma of the anus. European Journal of Cancer, 2021, 142, 147-149.	1.3	2
254	Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in FÃ©dÃ©ration Francophone de CancÃ©rologie Digestive (FFCD) trials. European Journal of Cancer, 2021, 153, 40-50.	1.3	2
255	Real-world safety and effectiveness of regorafenib in metastatic colorectal cancer: the French CORRELATE cohort. Future Oncology, 2021, 17, 3343-3353.	1.1	2
256	Final results of first European phase II trial of intravenous cetuximab (Cet) and hepatic artery infusion of irinotecan, 5-fluorouracil, and oxaliplatin in patients (pts) with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) after systemic treatment failure (OPTILIV,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6	0.8	2
257	Colorectal cancer (CRC) patients surveyed by 18FDGPET-CT (PET-CT): An open-label multicenter randomized trial (NCT 00624260).. Journal of Clinical Oncology, 2017, 35, 3520-3520.	0.8	2
258	Biliary cancers, chemotherapy, and cetuximab. Lancet Oncology, The, 2010, 11, 1110-1112.	5.1	1
259	Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica. Tumori, 2018, 104, NP38-NP41.	0.6	1
260	Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 601-608.	0.7	1
261	Obesity in metastatic colorectal cancer: Pooled analysis of FFCD trials.. Journal of Clinical Oncology, 2016, 34, 3532-3532.	0.8	1
262	Immunomodulatory switch maintenance therapy in metastatic colorectal carcinoma: The phase III IMPALA study.. Journal of Clinical Oncology, 2016, 34, TPS785-TPS785.	0.8	1
263	Fatigue and health behaviors in cancer survivors: A cross-sectional population based study.. Journal of Clinical Oncology, 2017, 35, 10069-10069.	0.8	1
264	EORTC1527/JCOG1609INT: Diffusion-weighted MRI (DW-MRI) assessment of liver metastasis to improve surgical planning (DREAM).. Journal of Clinical Oncology, 2017, 35, TPS3633-TPS3633.	0.8	1
265	Oxaliplatin desensitization after hypersensitivity reaction: A single-center experience on more than 300 procedures.. Journal of Clinical Oncology, 2018, 36, 610-610.	0.8	1
266	Four-year survival in patients (pts) undergoing liver surgery after neoadjuvant triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-CET) for previously treated and unresectable liver metastases from kras wt colorectal cancer (LM-CRC) (European trial OPTILIV, NCT00852228).. Journal of Clinical Oncology, 2014, 32, 3589-3589.	0.8	1
267	Chemotherapy for colorectal cancer â€“ Authors' reply. Lancet Oncology, The, 2012, 13, e4.	5.1	0
268	Traitement systÃ©mique des cancers biliaires avancÃ©s : prÃ©sent et futur. CancÃ©ro Digest, 2012, , .	0.0	0
269	Hepatic Resection for Extrahepatic Metastatic Disease: When Is It Reasonable?. Current Colorectal Cancer Reports, 2015, 11, 78-83.	1.0	0
270	Towards a RAS mutation status in a single day for patients with advanced colorectal cancers. Authorsâ€™ reply. Digestive and Liver Disease, 2018, 50, 974-975.	0.4	0

#	Article	IF	Citations
271	Sustained-hepatic arterial infusion of oxaliplatin: pharmacokinetic advantages over hepatic arterial infusion using a preclinical animal tumour model. Drug Delivery and Translational Research, 2021, 11, 2144-2150.	3.0	0
272	Metastatic Gastrointestinal Cancer: Safety of Cisplatin Combined with Continuous 5-FU Versus Bolus 5-FU and Leucovorin (Methodology). , 2008, , 13-21.		0
273	Developments in treating metastatic colorectal cancer: Recent international reports from ASCO 2007 and 2008. Clinical and Experimental Gastroenterology, 2009, 2, 13.	1.0	0
274	Abstract 4154: Intratumoral heterogeneity of HER2/neu expression in diffuse-gastric carcinoma of European patients and its relevance for patientsâ€™ management. , 2010, , .		0
275	Value of cardiophrenic angle lymph nodes for the diagnosis of colorectal peritoneal carcinomatosis.. Journal of Clinical Oncology, 2013, 31, 372-372.	0.8	0
276	Current use and attitudes toward the use of information technologies in health care among cancer patients.. Journal of Clinical Oncology, 2014, 32, e20652-e20652.	0.8	0
277	Axitinib in refractory colorectal metastatic cancer: A phase II study of increasing doses with dynamic contrast-enhanced ultrasonography monitory of the response.. Journal of Clinical Oncology, 2014, 32, 3638-3638.	0.8	0
278	Proportional shortfall due to pancreatic cancer in Europe: Survival and quality of life analysis based on a systematic review.. Journal of Clinical Oncology, 2014, 32, e15253-e15253.	0.8	0
279	Joint cell-line and patient modeling of drug sensitivity reveals novel molecular biomarkers for targeted and conventional chemotherapy.. Journal of Clinical Oncology, 2014, 32, 2565-2565.	0.8	0
280	Predictive ability of tumor growth modeling for overall survival in metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, e14619-e14619.	0.8	0
281	Impact of early tumor response on prognostic of patients with unresectable liver metastases from wt-KRAS colorectal cancer (LM-CRC) treated with hepatic artery infusion of irinotecan, 5-fluorouracil and oxaliplatin plus intravenous cetuximab after failure of systemic chemotherapy (European Phase II OPTILIV).. Journal of Clinical Oncology, 2016, 34, e15036-e15036.	0.8	0
282	REMINET: A European, multicentre, PHASE II/III randomized double-blind, placebo-controlled study evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.. Journal of Clinical Oncology, 2016, 34, TPS4148-TPS4148.	0.8	0
283	Vitamin K epoxide reductase complex subunit 1 (VKORC1): A pharmacogenomic predictor of response and survival in patients (pts) on triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-Cet) for initially unresectable liver metastases from colorectal cancer (uLM-CRC) (EU trial) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.8	0
284	Optimizing administration of third-line treatment in metastatic colorectal cancer.. Clinical Advances in Hematology and Oncology, 2021, 19 Suppl 24, 1-20.	0.3	0
285	Measures to mitigate treatment-related toxicities in third-line metastatic colorectal cancer.. Clinical Advances in Hematology and Oncology, 2021, 19 Suppl 24, 6-11.	0.3	0